Nothing said here yet.
to join the conversation.
Teva's pivot from generics to branded drugs has succeeded, but keep an eye out for this potential headwind.
Get a deeper insight into the potential performance of Teva Pharmaceutical Industries (TEVA) for the quarter ended September 2026 by going beyond Wall Street's top-and-bottom-line estimates and examining the estimates for some of its key metrics.
BXCL501, a dexmedetomidine sublingual film, is under FDA review for first-ever at-home use for the acute treatment of agitation associated with schizophrenia or bipolar I or II disorder in adultsAcquisition adds differentiated late-stage investigational asset…
Teva Pharmaceutical Industries stock: why WELTRUZA’s FDA approval matters now Teva Pharmaceutical Industries (NYSE:TEVA) just secured U.S. FDA approval for WELTRUZA, a once monthly injectable olanzapine treatment for adult schizophrenia, with a special call…
Analysts say that duvakitug could be differentiated from other pipeline TL1A candidates as the race to market heats up.
Teva Pharmaceutical Industries' (TEVA) affiliate Teva Pharmaceuticals and Sanofi (SNY) said Tuesday
In UC, duvakitug maintained high rates of clinical remission, clinical response, and endoscopic improvement at Week 44In CD, duvakitug maintained high rates of endoscopic response, clinical response, and clinical remission at Week 44Duvakitug was well…
TEL AVIV, Israel, Oct. 12, 2026 (GLOBE NEWSWIRE) -- Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) today announced that it will host an R&D Day on Wednesday, November 11, 2026.
Teva Pharmaceutical stock rallied Friday on FDA approval for Weltruza. But is it already too late to invest in TEVA shares? Let’s find out!
Teva wins FDA approval for Weltruza, the first once-monthly subcutaneous olanzapine injection for adults with schizophrenia, with a U.S. launch expected soon.
Hardman Johnston Global Advisors, an investment management firm, issued its Q3 2026 investor letter for the “Hardman Johnston International Equity Developed Markets Strategy”. The letter can be downloaded here.
Teva said it is debuting the drug to overcome adherence issues with an oral counterpart and improve symptom outcomes.